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Acridone based synthetic and natural products with inherent anticancer activity advancing the 
research and generating a large number of structurally diversified compounds. In this sequence we 
have designed, synthesized a series of tetracyclic acridones with amide framework viz., 3-(alkyloyl/ 
aryloyl/ heteroaryloyl/ heteroaryl)-2,3-dihydropyrazino[3,2,1-de]acridin-7(1H)-ones and screened for 
their in vitro anti-cancer activity. The in vitro study revealed that compounds with cyclopropyl-acetyl, 
benzoyl, p-hydroxybenzoyl, p-(trifluoromethyl)benzoyl, p-fluorobenzoyl, m-fluorobenzoyl, picolinoyl, 
6-methylpicolinoyl and 3-nicotinoyl groups are active against HT29, MDAMB231 and HEK293T cancer 
cell lines. The molecular docking studies performed for them against 4N5Y, HT29 and 2VWD revealed 
the potential ligand–protein binding interactions among the neutral aminoacid of the enzymes and 
carbonyl groups of the title compounds with a binding energy ranging from − 8.1394 to − 6.9915 kcal/
mol. In addition, the BSA protein binding assay performed for them has confirmed their interaction 
with target proteins through strong binding to BSA macromolecule. The additional studies like 
ADMET, QSAR, bioactivity scores, drug properties and toxicity risks ascertained them as newer drug 
candidates. This study had added a new collection of piperazino fused acridone derivatives to the 
existing array of other nitrogen heterocyclic fused acridone derivatives as anticancer agents.
Cancer is one of the leading diseases causing death worldwide and millions of people are getting affected every 
year and WHO estimates 12 million cancer deaths worldwide in  20301. Despite the great strides made in the 
treatment of cancer over the past 50 years, it continues to be a major health concern and therefore, extensive 
efforts have been devoted to search for novel scaffolds to develop chemo-therapeutics for the treatment of 
cancer. Although many drugs are available for its treatment, their resistance and low-specificity are the key 
challenges available for the medicinal  chemists2. Hence, the development of specific and potential anticancer 
drugs is a promising aspect of the moment. In such, many researchers have aimed to synthesize new anticancer 
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drugs, amongst such compounds acridone derivatives plays a key role as acridine based natural and synthetic 
compounds are a vital class of nitrogen heterocycles. These compounds are attentive as they exhibit an extensive 
array of pharmaceutical properties as it is being an integral part of natural products and important heterocycles 
in medicinal chemistry.
These acridone compounds are prompt to exhibit bioactivities like  anticancer3,  antimalarial4,5,  antitubercular6, 
 antiviral7,8, anti-inflammatory9,  antiparasitic10,  antimicrobial11,  fungicidal12, anti-psoriatic13, anti-candidiasis14 
and anti-biofilm15 activities. The acridone based alkaloids acronycine (I)16 and glyfoline (II)17 were found as 
potent human leukemia cell (HL60) growth inhibitors. The triazolo acridone derivatives C-1533 (IIIa) and 
C-1305 (IIIb) were known as anticancer agents against leukaemia, melanomas and colon adenocarcinoma cell 
 lines18. Similarly the imidazole fused acridone viz., symadex (IV) has been identified as antitumor  agent19,20. 
The pyrano fused acridone derivative viz., elacridar (V) is reported as a potent breast cancer resistance proteins 
 inhibitor21,22. Similarly, atalaphyllidine (VI) has been identified as human lung adenocarcinoma (A549) cell 
growth  inhibitors23. On the other hand acrifoline (VII), chlorospermine A (VIII) and chlorospermine B (IX) 
were reported as potential inhibitor of DYRK1A, a therapeutic cancer target which regulates the cell cycle pro-
gression of tumors and  oncogenes24,25.
Similarly, 2-hydroxyacridone (X) and its substituted derivatives were reported as DNA topoisomerase II 
and protein kinase C  inhibitors26 (Fig. 1). It is also reported that some of the synthesized fluorinated acridone 
derivatives as potent anticancer agents against MCF7, A549 and HT29 cell  lines27. Similarly, the versatile bio-
logical activity of acridone and piperazine hybrids/conjugates28 like multifunctional cholinesterase inhibition 
 acivity29, anticancer  agents30, and antimicrobial  activity31, hAChE and hBChE  inhibitors32. This striking seg-
ment stimulated us to conjugate piperazine ring onto parent acridone ring to greatly induce its potentiality. This 
hypothesis has been realized by generating a piperazine fused acridone ring that is appended with an amide 
linker comprising of alicyclic/ aromatic/ hetero-aromatic rings by N-aroylation/ N-aroylation. In ultimate this 
study has realized the concept making the newer molecules with enhanced lipophilicity and binding interac-
tions towards the interacting proteins. The merit of this accomplishment is that all existing nitrogen heterocycle 
fused acridone derivatives includes triazole, imidazole and pyrimidine rings in them, this is the first report 
on the synthesis and anticancer activity evaluation of the piperazine fused acridone derivatives. Moreover the 
tertiary amide linker (compared to the tertiary amines) impregnated on the piperazine ring has been proved as 
a prominent structural feature of the study.
Materials and methods
Chemistry. Reagent grade chemicals and analytical grade solvents were procured from Sigma-Aldrich and 
used for the synthesis, characterization and biological screening of title compounds. The analytical reagent [AR] 
grade solvents were purified by literature  methods33. TLC monitoring was performed on alumina supported 
silica gel 60 F254 plates (Merck, Darmstadt, Germany) and visualized under UV light. All 1H (400 MHz) and 13C 
NMR (400 MHz) spectra were recorded on Bruker NMR spectrometer. Chemical shifts were reported in ppm 
(δ) with reference to TMS (internal standard) using  CDCl3, DMSO-d6 and TFA as solvents. Coupling constant 
(J) values were given in Hertz and the multiplicities were designated as br, broad; s, singlet; d, doublet; t, triplet; 
m, multiplet. Molecular weights of the synthesized compounds were checked by SHIMADZU LCMS-2020 series 
in ESI mode. Melting points were recorded in capillaries and on Buchi Melting Point B-540 and are uncorrected. 
IR data was recorded on Perkin Elmer Spectrum 100. Column chromatography was performed with 100–200 
mesh silica.
Cytotoxicity assay. Anticancer activity of 7a–s has been evaluated by MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-tetrazolium bromide] assay and the cell lines HT29 (ATCC: HTB-38), MDA-MB-231 (ATCC: 
HTB-26), HEK293T (ATCC: CRL-3216) were procured from American type cell culture collection (ATCC), 
Manassas, USA and other chemicals were procured from Sigma-Aldrich. Then absorbance (used as a measure 
of cell proliferation) was measured at 570 nm with a kinetic micro-plate reader (BioTek, Winooski, Vermont).
Figure 1.  Natural products with acridone framework.
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Experimental
Chemistry. Novel 3-(alkyloyl/ aryloyl/ heteroaryloyl)-2,3-dihydropyrazino [3,2,1-de]acridin-7(1H)-ones 
and 3-(heteroaryl)-2,3-dihydro pyrazino [3,2,1-de]acridin-7(1H)-ones (7a–s) were designed by fusing of novel 
piperazine and acridone rings (Scheme  1). Synthetically, tetrahydroquinoxaline (2) is prepared from  NaBH4 
reduction of quinoxaline (1) in EtOH and protected with mono-Boc. Later the mono-Boc-protected tetrahydro-
quinoxaline (3) in toluene was reacted with methyl 2-bromobenzoate, in presence of  Cs2CO3–Pd(OAc)2–Xant-
phos catalyst system at 100 °C to form o-methyl ester derivative of tetrahydroquinoxaline (4). Then 4 on mild 
hydrolysis with LiOH produced its acid derivative 5, which up on 50% Sulfuric acid (50%  H2SO4) treatment 
produced the tetracyclic compound 6. Then on treating 6 with corresponding acids/ halides of alkyl/ aryl/ heter-
oaryl moieties produced 7a–s. The structures of all the synthesized compounds have been confirmed by IR, 1H, 
13C NMR, Mass spectral analytical and HPLC analytical studies and the spectra were provided in supplementary 
information.
1,2,3,4-Tetrahydroquinoxaline (2). Sodium  borohydride34  (NaBH4, 16.78 g, 441.83 mmol) was added 
to the mixture of quinoxaline (1, 23 g, 176.732 mmol) in ethanol (EtOH, 230 mL). Then it was purged with 
nitrogen, attached to mineral oil bubbler and stirred for 72 h at r.t. Then the same equivalent portion of  NaBH4 
in EtOH was added again and was purged for 48–72 h more. Then ethanol was evaporated under vacuum and 
the residue was dissolved in EtOAc (ethyl acetate) and washed with 3 M sodium hydroxide (NaOH), water and 
brine solution. Then organic phase was dried over anhydrous  Na2SO4 (sodium sulphate), solvent was distilled off 
and the residue obtained was triturated with hexane to isolate pure compound 2 (Yield: 97%; mp: 98–101 °C). 
IR (KBr,  cm−1) νmax: 3244 (NH); 1H NMR (400 MHz,  CDCl3): δ 6.59–6.55 (m, 2H), 6.50–6.46 (m, 2H), 3.58–3.51 
(br s, 2H), 3.40 (s, 4H); 13C NMR (400 MHz,  CDCl3): δ 133.62, 118.68, 114.64, 41.32; MS (ESI) [M + H]+ Calcd 
for  C8H10N2: 134.08; found: 135.07; HPLC: 97.34%.
t-Butyl 3,4-dihydroquinoxaline-1(2H)-carboxylate (3). Compound 2 obtained above was added 
with NaOH (8.23 g, 205.968 mmol) and boc anhydride (t-butoxycarbonyl anhydride, 19.69 mL, 85.82 mmol) 
in tetrahydrofuran (THF, 250 mL) and water (250 mL), the obtained reaction mixture was stirred for 16 h at r.t. 
Then the resulting contents were extracted with EtOAc and organic phase was dried over anhydrous  Na2SO4. 
Then the solvent was distilled off to obtain solid compound 3 (Yield: 50%; mp: 90–92 °C). IR (KBr,  cm−1) νmax: 
1673 (C=O), 3396 (NH); 1H NMR (400 MHz,  CDCl3): δ 7.49–7.47 (d, J = 6.4 Hz, 1H), 6.89–6.85 (t, J = 7.6 Hz, 
1H) 6.65–6.61 (t, J = 7.6 Hz, 1H), 6.54–6.52 (d, J = 8.0 Hz, 1H), 3.97 (br s 1H), 3.75–3.73 (t, J = 4.8 Hz, 2H), 
3.38–3.36 (t, J = 4.8 Hz, 2H), 1.51 (s, 9H); 13C NMR (400 MHz,  CDCl3): δ 153.23, 136.72, 124.60, 124.52, 116.52, 
114.44, 80.81, 41.97, 28.31; MS (ESI) [M + H]+ Calcd for  C13H18N2O2: 234.14; found: 235.34; HPLC: 98.37%.
t-Butyl 4-(2-(methoxycarbonyl) phenyl)-3,4-dihydroquinoxaline-1(2H)-carboxylate (4). To 
the mixture of compound 3 (3.0 g, 12.83 mmol) and methyl 2-bromobenzoate (5.51 g, 25.64 mmol), a catalytic 
system of cesium carbonate  (Cs2CO3, 10.44 g, 32.05 mmol), palladium(II) acetate (Pd(OAc)2, 0.01 mmol) and 
xantphos (9,9-Dimethyl-4,5-bis(diphenyl phosphino) xanthene, 0.01 mmol) were added in toluene (30 mL) and 
then degasified by purging nitrogen for 15 min and stirred for 16–17 h at 100 °C. Then the reaction mixture was 
extracted with EtOAc. The organic phase was dried over anhydrous  Na2SO4 and then solvent was distilled off 
and the residue was column chromatographed using EtOAc and hexane (5:1) as eluents and isolated compound 
4 (Yield: 72%; mp: 73–74 °C); IR (KBr,  cm−1) νmax: 1693 (O=C–Npiper), 1726 (O=C–Caryl), 2938 (C=C–Npiper); 1H 
Scheme 1.  Synthesis of 3-aryl/aroyl-2,3-dihydro-1H,7H-pyrazino[3,2,1-de]acridin-7-one derivatives.
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NMR (400 MHz,  CDCl3): δ 7.89–7.86 (dd, 1H, 2J = 8.0 Hz, 3J = 1.6 Hz, ArH), 7.59–7.54 (dt, 2J = 7.8 Hz, 3J = 1.6 Hz, 
1H) 7.50–7.48 (br d, J = 7.6 Hz, 1H), 7.34–7.31 (t, J = 7.6 Hz, 2H), 6.78–6.74 (dt, 2J = 8.0 Hz, 3J = 1.2 Hz, 1H) 
6.67–6.63 (dt, 2J = 8.2 Hz, 3J = 1.2 Hz, 1H) 6.26–6.24 (dd, 2J = 8.2 Hz, 3J = 1.0 Hz, 1H), 3.94–3.92 (t, J = 4.6 Hz, 2H), 
3.70–3.68 (t, J = 4.8 Hz, 2H), 3.62 (s, 3H), 1.55 (s, 9H); 13C NMR (400 MHz,  CDCl3): δ 167.08, 153.22, 146.13, 
137.82, 133.65, 131.88, 130.04, 129.72, 126.31, 125.35, 124.73, 124.51, 116.97, 113.71, 80.95, 52.13, 51.328, 41.38, 
28.41; MS (ESI) [M + H]+ calcd for  C21H24N2O4: 368.43; found, 369.46; HPLC: 98.95%.
2-(4-(t-Butoxycarbonyl)-3,4-dihydroquinoxalin-1(2H)-yl)benzoic acid (5). A mixture of com-
pound 4 (20  g, 54.34  mmol), lithium hydroxide (LiOH) monohydrate (11.40  g, 543.47  mmol) in methanol 
(100 mL) and water (50 mL) was stirred for 16–17 h at r.t. The solvent distilled off and the residue was extracted 
with EtOAc. The organic phase was dried over anhydrous  Na2SO4 and solvent distilled out to isolate pure 
compound 5 (Yield: 83.2%; mp: 169–171 °C); IR (KBr,  cm−1) νmax: 1593 (C=O), 1699 (C=O), 3443 (OH): 1H 
NMR (400 MHz, DMSO-d6): δ 12.83 (s, 1H, COOH), 7.85–7.82 (dd, 2J = 7.8 Hz, 3J = 1.2 Hz, 1H), 7.67–7.63 (dt, 
2J = 7.6 Hz, 3J = 1.2 Hz, 1H), 7.44–7.37 (m, 3H, ArH), 6.73–6.69 (dt, 2J = 8.4 Hz, 3J = 1.4 Hz, 1H), 6.57–6.53 (dt, 
2J = 8.2 Hz, 3J = 1.2 Hz, 1H), 6.06–6.03 (dd, 2J = 8.2 Hz, 3J = 1.0 Hz, 1H), 3.81–3.79 (t, J = 4.8 Hz, 2H), 3.61–3.59 (t, 
J = 4.6 Hz, 2H), 1.46 (s, 9H); 13C NMR (400 MHz, DMSO-d6): δ 167.40, 152.36, 144.82, 137.54, 133.53, 131.19, 
131.13, 130.18, 126.79, 124.40, 124.16, 115.83, 112.46, 80.25, 50.50, 40.72, 40.12, 27.96; MS (ESI) [M + H]+ calcd 
for  C20H22N2O4: 354.40; found: 355.15; HPLC: 98.79%.
3-Dihydropyrazino[3,2,1-de]acridin-7(1H)-one (6). 50%  H2SO414 in water (15 mL, 15 v/w) and com-
pound 5 (1 g, 2.824 mmol) stirred for 6–7 h at r.t. Reaction mixture was poured into ice cold water and extracted 
with EtOAc. The organic phase was dried over anhydrous  Na2SO4. The solvent distilled off and the residue was 
column chromatographed using EtOAc and hexane (7:1) as eluents and isolated pure compound 6 (Yield: 63%; 
mp: 225–227 °C); IR (KBr,  cm−1) νmax: 1602 (C=O), 3270 (NH); 1H NMR (400 MHz, DMSO-d6): δ 8.33 (d, 1H, 
J = 8.0 Hz), 7.79–7.74 (m, 2H), 7.60–7.58 (m, 1H), 7.30 (t, 1H, J = 7.2 Hz), 7.07–6.99 (m, 2H), 6.42 (s, 1H, NH), 
4.34 (t, 2H, J = 5.0 Hz), 3.52 (t, 2H, J = 4.4 Hz); 13C NMR (400 MHz, DMSO-d6): δ 176.33, 140.75, 137.40, 133.51, 
129.36, 126.51, 121.72, 121.42, 120.93, 120.85, 115.59, 114.78, 114.13, 44.92, 40.12. MS (ESI) [M + H]+: calcd for 
 C15H12N2O: 236.27; found: 237.12; HPLC: 97.54%.
3-(Alkyloyl/ aryloyl/ heteroaryloyl)-2,3-dihydropyrazino [3,2,1-de]acridin-7(1H)-ones35. Pro-
cedure A. Mixture of 6 (1.0 mmol) and suitable carboxylic acid (1.0 mmol) was treated with  POCl3 (1.5 mmol) 
and pyridine (3.0 mmol) in Tetrahedrofuran (10 volumes) at r.t. for 16 h. On completion of reaction, it was 
extracted into EtOAc and organic phase was dried over anhydrous  Na2SO4. Then the solvent was distilled off and 
the residue was column chromatographed using EtOAc and hexane (10:1) to isolate 7a–i and 7k–r in pure form.
3-(Heteroaryl)-2,3-dihydropyrazino [3,2,1-de]acridin-7(1H)-ones. Procedure B. Mixture of 6 
(1.0 mmol) and appropriate bromide (3.0 mmol) was treated with  Na2CO3 (6.0 mmol) in ethanol (10volumes) 
at r.t. for 16 h. On completion of reaction, solvent was distilled out and extracted with EtOAc. The organic phase 
was dried over anhydrous  Na2SO4. Then the solvent was distilled off and the residue was column chromato-
graphed using EtOAc and hexane (10:1) as eluents to isolate 7j and 7s in pure form.
3-Picolinoyl-2,3-dihydropyrazino[3,2,1-de]acridin-7(1H)-one (7a). Yellow solid, Yield: 156.0 mg 
(71.9%); mp: 232–234 °C; IR (KBr,  cm−1) νmax: 1633 (C=O), 1650 (C=O); 1H NMR (400 MHz, DMSO-d6): δ 8.49 
(br s, 1H), 8.37–8.35 (d, J = 8.0 Hz, 1H), 8.08 (br s, 1H), 7.95 (br s, 1H), 7.91–7.87 (t, J = 7.8 Hz, 1H), 7.77–7.75 (d, 
J = 8.0 Hz, 2H), 7.50 (br s, 1H), 7.42–7.38 (t, J = 7.4 Hz, 1H), 7.05 (br s, 2H), 4.46 (s, 2H), 4.28 (s, 2H); 13C NMR 
(400 MHz, DMSO-d6): δ 176.13, 166.48, 153.07, 148.46, 141.05, 137.46, 134.27, 132.62, 127.85, 126.46, 125.22, 
124.09, 123.01, 121.85, 121.78, 121.17, 119.99, 115.09, 46.25; MS (ESI) [M + H]+ Calcd for  C21H15N3O2: 341.36; 
found: 342.1; HPLC: 98.01%.
3-Nicotinoyl-2,3-dihydropyrazino[3,2,1-de]acridin-7(1H)-one (7b). Yellow solid; Yield: 142.0 mg 
(65.5%); mp: 231–233 °C; IR (KBr,  cm−1) νmax: 1607 (C=O), 1633 (C=O); 1H NMR (400 MHz, DMSO-d6): δ 8.65 
(s, 1H), 8.62–8.61 (d, J = 3.6 Hz, 1H), 8.38–8.36 (dd, 2J = 7.8 Hz, 3J = 1.4 Hz, 1H), 8.09–8.07 (d, J = 8.0 Hz, 1H), 
7.92–7.87 (m, 2H, ArH), 7.78–7.76 (d, J = 8.8 Hz, 1H), 7.43–7.39 (t, J = 7.2 Hz, 2H), 7.26 (br s, 1H), 7.04 (br s, 
1H), 4.52–4.50 (t, J = 5.0 Hz, 2H), 4.27 (s, 2H); 13C NMR (400 MHz, DMSO-d6): δ 176.14, 163.00, 150.96, 149.08, 
141.13, 136.20, 134.20, 132.60, 130.93, 128.41, 127.48, 126.43, 123.17, 121.80, 121.21, 119.81, 115.13, 46.11; MS 
(ESI) [M + H]+ Calcd for  C21H15N3O2: 341.36; found: 342.12; HPLC: 98.78%.
3-Isonicotinoyl-2,3 dihydropyrazino[3,2,1-de]acridin-7(1H)-one (7c). Yellow solid, Yield: 
148.0 mg (68.5%); mp: 233–235 °C; IR (KBr,  cm−1) νmax: 1635 (C=O), 1648 (C=O); 1H NMR (400 MHz, DMSO-
d6): δ 8.63 (s, 2H), 8.38–8.35 (dd, 2J = 8.2 Hz, 3J = 1.4 Hz, 1H), 8.11–8.09 (d, J = 8.0 Hz, 1H), 7.91–7.87 (m, 1H, 
ArH), 7.77–7.75 (d, J = 8.8  Hz, 1H), 7.47 (s, 1H), 7.42–7.39 (t, J = 7.4  Hz, 2H), 7.06 (br s, 2H), 4.49 (s, 2H), 
4.23 (s, 2H); 13C NMR (400 MHz, DMSO-d6): δ 176.13, 166.18, 149.95, 142.65, 141.12, 134.25, 132.67, 128.32, 
126.95, 126.46, 123.44, 122.21, 121.85, 121.79, 121.23, 119.81, 115.13, 46.01, 40.12; MS (ESI) [M + H]+ Calcd for 
 C21H15N3O2: 341.36; found: 342.06: HPLC: 98.02%.
3-(2-Cyclopropylacetyl)-2,3-dihydropyrazino[3,2,1-de]acridin-7(1H)-one (7d). Pale yel-
low solid; Yield: 42.0 mg (31.1%); mp: 238–240 °C; IR (KBr,  cm−1) νmax: 1594 (C=O), 1625 (C=O); 1H NMR 
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(400 MHz, DMSO-d6): δ 8.36–8.33 (dd, 2J = 7.8 Hz, 3J = 1.4 Hz, 1H), 8.16–8.14 (dd, 2J = 8.0 Hz, 3J = 1.2 Hz, 1H), 
7.89–7.85 (m, 2H, ArH), 7.75–7.73 (d, J = 8.8  Hz, 1H), 7.41–7.37 (t, J = 7.4  Hz, 1H), 7.31–7.27 (t, J = 7.8  Hz, 
1H), 4.34 (s, 2H), 4.16 (s, 2H), 2.56–2.54 (d, J = 6.4 Hz, 2H), 0.98 (s, 1H), 0.43 (s, 2H), 0.09 (s, 2H); 13C NMR 
(400 MHz, DMSO-d6): δ 176.22, 170.87, 141.11, 134.19, 133.02, 128.33, 126.41, 121.79, 121.17, 120.18, 115.13, 
46.36; MS (ESI) [M + H]+ Calcd for  C20H18N2O2: 318.37; found: 319.21; HPLC: 98.46%.
3-(6-Methylpicolinoyl)-2,3-dihydropyrazino[3,2,1-de]acridin-7(1H)-one (7e). Pale yellow solid; 
Yield: 64.0 mg (42.5%); mp: 246–248 °C; IR (KBr,  cm−1) νmax: 1597 (C=O), 1634 (C=O); 1H NMR (400 MHz, 
DMSO-d6): δ 8.33–8.32 (d, J = 6.8 Hz, 1H), 8.06 (s, 1H), 7.86–7.70 (m, 3H, ArH), 7.48 (s, 1H), 7.38–7.34 (t, 
J = 7.6 Hz, 2H), 7.11 (br s, 2H), 4.41 (s, 2H), 4.20 (s, 2H), 2.37 (s, 3H); 13C NMR (400 MHz, DMSO-d6): δ 176.14, 
166.55, 150.31, 148.58, 141.04, 137.59, 135.00, 134.25, 132.56, 127.79, 126.46, 123.80, 122.88, 121.82, 121.78, 
121.15, 120.02, 115.08, 46.28, 17.90; MS (ESI) [M + H]+ Calcd for  C22H17N3O2: 355.39; found: 356.15: HPLC: 
91.00%.
3-(5-Methylpicolinoyl)-2,3-dihydropyrazino[3,2,1-de]acridin-7(1H)-one (7f). Yellow solid; 
Yield: 90.0 mg (59.8%); mp: 252–254 °C; IR (KBr,  cm−1) νmax: 1598 (C=O), 1636 (C=O); 1H NMR (400 MHz, 
DMSO-d6): δ 8.37–8.35 (d, J = 7.2 Hz, 2H), 8.09–8.07 (d, J = 6.8 Hz, 1H), 7.90–7.87 (t, J = 7.4 Hz, 1H), 7.66–7.74 
(d, J = 8.4 Hz, 2H), 7.68–7.66 (d, J = 8.0 Hz, 1H), 7.42–7.38 (t, J = 7.4 Hz, 1H), 7.09 (br s, 2H), 4.45 (s, 2H), 4.28 
(s, 2H), 2.34 (s, 3H); 13C NMR (400 MHz, DMSO-d6): δ 176.14, 166.55, 150.31, 148.58, 141.04, 137.59, 135.00, 
134.25, 132.56, 127.79, 126.46, 123.80, 122.88, 121.82, 121.78, 121.15, 120.02, 115.08, 46.28, 17.90; MS (ESI) 
[M + H]+ Calcd for  C22H17N3O2: 355.39; found: 355.81; HPLC: 97.42%.
3-(3-Methylpicolinoyl)-2,3-dihydropyrazino[3,2,1-de]acridin-7(1H)-one (7g). Yellow solid; 
Yield: 52.0 mg (34.5%); mp: 221–223 °C; IR (KBr,  cm−1) νmax: 1599 (C=O), 1661 (C=O); 1H NMR (400 MHz, 
TFA): δ 8.77–8.75 (d, J = 8.4 Hz, 1H), 8.66–8.64 (d, J = 7.6 Hz, 2H), 8.49 (s, 1H), 8.29–8.25 (t, J = 7.8 Hz, 1H), 8.13 
(s, 1H), 8.02 (s, 1H), 7.86–7.82 (t, J = 7.8 Hz, 1H), 7.51 (br s, 2H), 5.12 (s, 2H), 4.45 (s, 2H), 2.52 (s, 3H); 13C NMR 
(400 MHz, DMSO-d6): δ 176.14, 166.55, 150.31, 148.58, 141.04, 137.59, 135.0, 134.25, 132.56, 127.79, 126.46, 
123.80, 122.88, 121.82, 121.78, 120.02, 115.08, 46.28, 17.90; MS (ESI) [M + H]+ Calcd for  C22H17N3O2: 355.39; 
found: 356.20; HPLC: 99.62%.
3-(Thiophene-3-carbonyl)-2,3-dihydropyrazino[3,2,1-de]acridin-7(1H)-one (7h). Yellow solid; 
Yield: 66.0 mg (45.0%); mp: 254–256 °C; IR (KBr,  cm−1) νmax: 1608 (C=O), 1637 (C=O); 1H NMR (400 MHz, 
DMSO-d6): δ 8.38–8.35 (dd, 2J = 8.0 Hz, 3J = 1.6 Hz, 1H), 8.11–8.08 (dd, 2J = 8.2 Hz, 3J = 1.4 Hz, 1H), 7.91–7.86 
(m, 2H, ArH), 7.76–7.74 (t, J = 8.4 Hz, 1H), 7.55–7.53 (m, 1H, ArH), 7.42–734 (m, 2H, ArH), 7.12–7.08 (m, 
2H, ArH), 4.45 (s, 2H), 4.26 (s, 2H). 13C NMR (400 MHz, DMSO-d6): δ 176.19, 163.51, 141.08, 135.84, 134.16, 
132.48, 130.03, 127.89, 127.83, 127.73, 126.49, 126.43, 122.87, 121.83, 121.71, 121.17, 119.88, 115.08, 46.22; MS 
(ESI) [M + H]+ Calcd for  C20H14N2O2S: 346.08; found: 347.21; HPLC: 98.18%.
3-(6-(Trifluoromethyl)picolinoyl)-2,3-dihydropyrazino[3,2,1-de]acridin-7(1H)-one (7i). Yel-
low solid; Yield: 62.0 mg (35.7%); mp: 234–236 °C; IR (KBr,  cm−1) νmax: 1606 (C=O), 1636 (C=O); 1H NMR 
(400 MHz, DMSO-d6): δ 8.87 (s, 1H), 8.39–8.36 (dd, 2J = 8.0 Hz, 3J = 1.2 Hz, 1H), 8.18 (s, 1H), 8.12–8.10 (d, 
J = 8.0 Hz, 1H), 7.95–7.88 (m, 2H, ArH), 7.79–7.77 (d, J = 8.8 Hz, 1H), 7.43–7.40 (t, J = 7.6 Hz, 1H), 7.06 (br s, 
2H), 4.52 (s, 2H), 4.29 (s, 2H); 13C NMR (400 MHz, DMSO-d6): δ 176.12, 141.13, 134.26, 132.75, 128.54, 126.46, 
123.56, 121.85, 121.25, 120.38, 119.82, 115.11, 46.00; MS (ESI) [M + H]+ Calcd for  C22H14F3N3O2: 409.36; found: 
410.14: HPLC: 99.93%.
3-(Thiazol-2-yl)-2,3-dihydropyrazino[3,2,1-de]acridin-7(1H)-one (7j). Pale yellow solid; Yield: 
92.0 mg (68%); mp: 239–241 °C; IR (KBr,  cm−1) νmax: 1593 (C=O), 1626 (C=O); 1H NMR (400 MHz, DMSO-
d6): δ 8.37–8.35 (dd, 2J = 8.0  Hz, 3J = 1.6  Hz, 1H), 8.19–8.17 (dd, 2J = 7.8  Hz, 3J = 1.4  Hz, 1H), 8.14–8.12 (dd, 
2J = 8.0 Hz, 3J = 1.6 Hz, 1H), 7.89–7.70 (dt, 2J = 8.0 Hz, 3J = 1.6 Hz, 1H), 7.79–7.77 (d, J = 8.4 Hz, 1H), 7.41–7.31 
(m, 3H, ArH), 7.06–7.05 (d, J = 3.6 Hz, 1H), 4.42–4.40 (d, J = 5.6 Hz, 2H), 4.36–4.35 (d, J = 5.6 Hz, 2H); 13C NMR 
(400 MHz, DMSO-d6): δ 176.17, 167.72, 140.95, 139.28, 134.11, 132.04, 130.74, 126.42, 124.38, 122.23, 122.08, 
121.77, 121.17, 120.63, 115.09, 110.31, 44.33, 44.16; MS (ESI) [M + H]+ Calcd for  C18H13N3OS: 319.38; found: 
320.19: HPLC: 98.29%.
3-(4-hydroxybenzoyl)-2,3-dihydro-1H,7H-pyrazino[3,2,1-de]acridin-7-one (7k). Yellow solid; 
Yield: 40.0 mg (26.6%); mp: 265–267 °C; IR (KBr,  cm−1) νmax: 1570 (C=O), 1654 (C=O); 1H NMR (400 MHz, 
DMSO-d6): δ 10.70–9.70 (bs, 1H), 8.38–8.33 (m, 1H), 8.06–8.04 (m, 1H), 7.90–7.87 (m, 1H), 7.77–7.75 (m, 
1H), 7.41–7.31 (m, 3H), 7.26–7.19 (m, 1H), 7.08–7.04 (m, 1H), 6.74–6.72 (m, 2H), 4.47–4.44 (m, 2H), 4.23 (bs, 
2H); 13C NMR (400 MHz, DMSO-d6): δ 176.26, 168.28, 159.95, 141.11, 134.23, 132.25, 130.92, 128.72, 128.00, 
126.48, 124.77, 122.36, 121.85, 121.76, 121.17, 120.00, 115.19, 114.97, 79.25, 46.36; MS (ESI) [M + H]− Calcd for 
 C22H16N2O3: 356.38; found: 356.96; HPLC: 97.58%.
3-Benzoyl-2,3-dihydro-1H,7H-pyrazino[3,2,1-de]acridin-7-one (7l). Yellow solid; Yield: 35.0 mg 
(48.6%); mp: 253–255 °C; IR (KBr,  cm−1) νmax: 1628 (C=O), 1655 (C=O); 1H NMR (400 MHz,  CDCl3): δ 8.61–
8.56 (m, 1H), 8.31–8.25 (m, 1H), 7.83–7.76 (m, 1H), 7.55–7.47 (m, 1H), 7.46–7.28 (m, 6H), 7.09–6.99 (s, 1H), 
6.98–6.91 (m, 1H), 4.42 (s, 4H); 13C NMR (400 MHz,  CDCl3): δ 177.82, 169.01, 141.59, 134.49, 132.73, 131.25, 
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129.05, 128.71, 128.20, 127.97, 124.64, 123.06, 122.44, 120.52, 113.86, 47.01, 40.45; MS (ESI) [M + H]− Calcd for 
 C22H16N2O2: 340.12; found: 340.81; HPLC: 99.51%
3-(2-(Trifluoromethyl)benzoyl)-2,3-dihydro-1H,7H-pyrazino[3,2,1-de]acridin-7-one 
(7m). Yellow solid; Yield: 45.0 mg (52%); mp: 252–254 °C; IR (KBr,  cm−1) νmax: 1637 (C=O), 1505 (C=O); 
1H NMR (400 MHz,  CDCl3): δ 8.63–8.53 (m, 1H), 8.47–8.33 (m, 1H), 8.30–8.18 (m, 1H), 7.89–7.59 (m, 3H), 
7.60–7.44 (m, 2H), 7.43–7.30 (m, 2H), 6.88–6.72 (m, 1H), 4.55–4.40 (m, 2H), 4.29–4.19 (m, 1H), 3.94–3.84 
(m, 1H); 13C NMR (400 MHz,  CDCl3): δ 177.42, 166.89, 157.84, 141.33, 134.26, 132.66, 131.71, 129.98, 128.46, 
127.88, 126.97, 125.04, 122.69, 122.22, 120.79, 119.94, 113.66, 113.15, 45.91, 38.81; MS (ESI) [M + H]− Calcd for 
 C23H15F3N2O2: 408.11; found: 408.94; HPLC: 99.33%.
3-(3-(Trifluoromethyl)benzoyl)-2,3-dihydro-1H,7H-pyrazino[3,2,1-de]acridin-7-one 
(7n). Yellow solid; Yield: 50.0 mg (58%); mp: 247–249 °C; IR (KBr,  cm−1) νmax: 1637 (C=O), 1505 (C=O); 1H 
NMR (400 MHz,  CDCl3): δ 8.62–8.58 (m, 1H), 8.34–8.29 (m, 1H), 7.84–7.77 (m, 2H), 7.69 (d, J = 7.7 Hz, 1H), 
7.54–7.47 (m, 2H), 7.44–7.37 (m, 2H), 7.00–6.92 (m, 2H), 4.45 (s, 4H); 13C NMR (400 MHz,  CDCl3): δ 177.08, 
166.60, 140.98, 134.73, 133.97, 132.15, 131.59, 131.11, 130.70, 128.50, 127.98, 127.64, 127.28, 126.72, 125.66, 
124.60, 122.55, 121.94, 119.85, 113.24, 46.30, 39.84; MS (ESI) [M + H]− Calcd for  C23H15F3N2O2: 408.11; found: 
408.9; HPLC: 98.21%.
3-(4-(Trifluoromethyl)benzoyl)-2,3-dihydro-1H,7H-pyrazino[3,2,1-de]acridin-7-one 
(7o). Pale yellow solid; Yield: 25.0 mg (29%); mp: 240–242 °C; IR (KBr,  cm−1) νmax: 1637 (C=O), 1602 (C=O); 
1H NMR (400 MHz, DMSO-d6): δ 8.37 (d, 1H, J = 7.6 Hz), 8.09 (d, 1H, J = 8 Hz), 7.90 (t, 1H, J = 7.4 Hz), 7.78–
7.73 (m, 6H), 7.41 (t, 1H, J = 7.2 Hz), 7.06 (br s, 1H), 4.51 (br s, 2H), 4.26 (br s, 2H); 13C NMR (400 MHz, DMSO-
d6): δ 176.18, 141.15, 134.32, 128.41, 126.50, 125.34, 123.28, 121.89, 121.83, 121.24, 119.91, 115.19; MS (ESI) 
[M + H]− Calcd for  C23H15F3N2O2: 408.11; found: 408.94; HPLC: 97.15%.
3-(2-Fluorobenzoyl)-2,3-dihydro-1H,7H-pyrazino[3,2,1-de]acridin-7-one (7p). Yellow solid; 
Yield: 45.0  mg (60%); mp: 225–227  °C; IR (KBr,  cm−1) νmax: 1650 (C=O), 1594 (C=O); 1H NMR (400  MHz, 
 CDCl3): δ 8.60–8.52 (m, 1H), 8.31–8.26 (m, 1H), 7.82–7.77 (m, 1H), 7.49 (m, 1H), 7.37 (m, 1H), 7.30–7.29 (m, 
1H), 7.24–7.23 (m, 1H), 7.22–7.10 (m, 3H), 6.98–6.94 (m, 1H), 4.46–4.37 (m, 4H); 13C NMR (400 MHz,  CDCl3): 
δ 172.25, 171.42, 161.13, 155.35, 154.53, 148.63, 138.74, 138.17, 135.13, 128.22, 128.02, 127.86, 115.66, 117.20, 
113.59, 80.01, 50.92, 50.60; MS (ESI) [M + H]− Calcd for  C22H15FN2O2: 358.11; found: 359.03; HPLC: 98.59%.
3-(3-Fluorobenzoyl)-2,3-dihydro-1H,7H-pyrazino[3,2,1-de]acridin-7-one (7q). Yellow solid; 
Yield: 30.0 mg (40%); mp: 242–244 °C; IR (KBr,  cm−1) νmax: 1650 (C=O), 1603 (C=O); 1H NMR (400 MHz,  CDCl3): 
δ 8.61–8.56 (m, 1H), 8.32–8.27 (m, 1H), 7.83–7.76 (m, 1H), 7.49 (d, J = 8.68 Hz, 1H), 7.37 (t, J = 7.45 Hz, 1H), 7.31–
7.28 (m, 1H), 7.25–7.23 (m, 1H), 7.22–7.09 (m, 3H), 6.99–6.94 (m, 1H), 4.46–4.38 (m, 4H); 13C NMR (400 MHz, 
 CDCl3): δ 177.00, 166.84, 163.26, 160.79, 140.86, 136.09, 133.83, 132.04, 129.79, 129.71, 127.85, 127.44, 124.24, 
123.99, 121.75, 119.83, 117.73, 117.52, 115.66, 115.43, 113.20, 46.24; MS (ESI) [M + H]− Calcd for  C22H15FN2O2: 
358.11; found: 359.03; HPLC: 99.50%.
3-(4-Fluorobenzoyl)-2,3-dihydro-1H,7H-pyrazino[3,2,1-de]acridin-7-one (7r). Yellow solid; 
Yield: 25.0  mg (33%); mp: 236–238  °C; IR (KBr,  cm−1) νmax: 1630 (C=O), 1600 (C=O); 1H NMR (400  MHz, 
 CDCl3): δ 8.62 -8.58 (m, 1H), 8.35–8.25 (m, 1H), 7.85–7.68 (m, 1H), 7.55–7.45 (m, 1H), 7.42–7.38 (m, 3H), 
7.10–6.87 (m, 4H), 4.45–4.37 (m, 4H); 13C NMR (400 MHz,  CDCl3): δ 177.00, 166.84, 163.26, 160.79, 140.86, 
136.09, 133.83, 132.04, 129.39, 127.85, 127.44, 124.24, 121.75, 119.83, 117.52, 115.43, 113.20, 46.24, 39.89, 26.60; 
MS (ESI) [M + H]− Calcd for  C22H15FN2O2: 358.11; found: 359.03; HPLC: 98.60%.
3-(Pyridin-3-yl)-2,3-dihydropyrazino[3,2,1-de]acridin-7(1H)-one (7s). Yellow solid; Yield: 
41.0 mg (31.6%); mp: 244–246 °C; IR (KBr,  cm−1) νmax: 1549 (C=O), 1621 (C=O); 1H NMR (400 MHz, DMSO-
d6): δ 8.65 (s, 1H), 8.37–8.36 (d, J = 7.6 Hz, 2H), 7.92–7.78 (m, 4H, ArH), 7.58 (s, 1H), 7.39–7.36 (t, J = 7.0 Hz, 1H), 
7.26–7.24 (d, J = 7.6 Hz, 1H), 7.12 (t, J = 7.4 Hz, 1H), 4.47 (s, 2H), 4.08 (s, 2H); 13C NMR (400 MHz, DMSO-d6): 
δ 176.27, 143.04, 141.38, 140.75, 133.95, 133.35, 131.48, 131.25, 126.43, 125.14, 122.23, 121.48, 121.00, 120.91, 
119.04, 118.98, 115.07, 44.81. MS (ESI) [M + H]+ Calcd for  C20H15N3O: 313.35; found: 314.15; HPLC: 89.86%.
Cytotoxicity assay. Having synthesized a series of the title compounds, all of them were screened for their 
in vitro anticancer profiles against a panel of human colorectal adenocarcinoma (HT29), human breast adeno-
carcinoma (MDA-MB-231) and mutated Human embryonic kidney 293 (HEK293T) cancer cell lines by using 
MTT colourmetric assay as per Johan van Meerloo  protocol36. The three cell lines were cultured in RPMI-1370 
medium and supplemented with 10% FBS followed by 100 units/mL penicillin/ streptomycin and were cultured 
at 37 °C in 5%  CO2. Cell proliferation of the growing cells was measured in terms of logarithmic standards. Ana-
lytically, all the cultured cells were plated onto 96 well plates at a starting density of  105 cells. Then all the cells 
were treated with title compounds 7a–s for a period of 48 h with different concentrations. After this incubation 
cell proliferation inhibition was determined by MTT assay and all the experiments were conducted in triplicates 
and readings were presented as mean ± SD and provided in Tables 1, 2 and 3.
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Molecular docking studies. The mechanistic inhibition of cancer cell proliferation in vitro by 7a–s has 
been arbitrated by molecular docking interactions studies. In the course, the crystal structures of proteins were 
acquired as PDB files from protein data bank and considered after removal of bound water, ligands and cofac-
tors from the environment. The .pdb files and .mol2 files of 7a–s were produced from Chem3D Pro 14.0 of 
ChemBioOffice software and docked with the selected proteins on Swiss  Dock37. In view of prompt concerns of 
anti-cancer potentiality, study has been protracted to the standard Doxorubicin.
Table 1.  MTT assay of 7a–s against HT29.
Compound
Percentage of inhibition against treated concentrations (µM)
IC50 (µg/mL)1 5 10 25 50
7a 78.91 ± 0.42 57.61 ± 0.39 44.06 ± 0.86 14.88 ± 0.36 8.77 ± 0.72 11.24 ± 0.68
7b 89.93 ± 0.66 65.63 ± 0.27 52.51 ± 0.82 38.08 ± 0.42 19.44 ± 0.35 20.72 ± 0.49
7c 90.02 ± 0.31 66.19 ± 0.83 52.93 ± 0.84 40.37 ± 0.15 20.79 ± 0.08 21.57 ± 0.31
7d 88.71 ± 0.78 63.12 ± 0.71 50.91 ± 0.38 29.68 ± 0.23 17.97 ± 0.39 18.26 ± 0.29
7e 84.92 ± 0.94 60.82 ± 0.33 49.12 ± 0.85 27.59 ± 0.35 16.26 ± 0.55 16.36 ± 0.48
7f 86.92 ± 0.24 61.38 ± 0.68 49.24 ± 0.05 29.09 ± 0.18 17.14 ± 0.65 17.19 ± 0.46
7g 79.09 ± 0.34 58.87 ± 0.93 45.11 ± 0.54 25.48 ± 0.44 10.01 ± 0.91 13.22 ± 0.57
7h 87.92 ± 0.24 62.38 ± 0.68 50.24 ± 0.65 29.49 ± 0.51 17.84 ± 0.65 17.85 ± 0.66
7i 83.56 ± 0.57 59.11 ± 0.75 46.51 ± 0.52 25.83 ± 0.28 12.22 ± 0.27 14.63 ± 0.14
7j 89.55 ± 0.11 64.84 ± 0.45 51.48 ± 0.94 31.05 ± 0.19 17.37 ± 0.87 18.86 ± 0.38
7k 96.62 ± 0.99 81.84 ± 0.11 74.68 ± 0.64 66.23 ± 0.18 28.03 ± 0.96 33.63 ± 0.21
7l 97.17 ± 0.22 83.16 ± 0.99 76.71 ± 0.06 68.88 ± 0.47 30.59 ± 0.87 35.55 ± 0.29
7m 92.71 ± 0.01 76.71 ± 0.17 68.51 ± 0.72 57.33 ± 0.32 23.79 ± 0.33 29.09 ± 0.93
7n 95.32 ± 0.73 79.12 ± 0.33 72.72 ± 0.33 59.26 ± 0.11 26.92 ± 0.84 31.35 ± 0.24
7o 93.92 ± 0.39 77.83 ± 0.91 69.54 ± 0.24 58.23 ± 0.26 24.32 ± 0.76 29.72 ± 0.32
7p 90.43 ± 0.77 74.71 ± 0.22 65.84 ± 0.76 54.13 ± 0.37 20.98 ± 0.22 26.94 ± 0.97
7q 94.96 ± 0.53 78.87 ± 0.43 70.57 ± 0.53 58.23 ± 0.29 25.33 ± 0.44 30.32 ± 0.86
7r 91.94 ± 0.93 75.12 ± 0.73 66.15 ± 0.13 55.26 ± 0.23 21.57 ± 0.24 27.52 ± 0.50
7s 84.78 ± 0.12 60.38 ± 0.24 48.41 ± 0.57 27.49 ± 0.35 15.21 ± 0.61 15.98 ± 0.44
Doxorubicin 97.09 ± 0.79 90.76 ± 0.83 82.92 ± 0.54 72.56 ± 0.83 42.76 ± 0.86 43.81 ± 0.57
Table 2.  MTT assay of 7a–s against MDAMB231.
Compound
Percentage of inhibition against treated concentrations (µM)
IC50 (µg/mL)1 5 10 25 50
7a 84.42 ± 0.35 55.22 ± 0.46 44.52 ± 0.29 24.96 ± 0.27 14.71 ± 0.42 13.82 ± 0.51
7b 86.22 ± 0.83 56.42 ± 0.47 46.91 ± 0.44 32.3 ± 0.16 19.03 ± 0.62 16.57 ± 0.63
7c 86.77 ± 0.96 57.39 ± 0.32 47.21 ± 0.93 38.69 ± 0.28 22.8 ± 0.89 18.75 ± 0.49
7d 85.23 ± 0.73 55.73 ± 0.21 45.64 ± 0.98 28.57 ± 0.43 16.83 ± 0.16 15.09 ± 0.12
7e 82.18 ± 0.79 52.86 ± 0.75 42.09 ± 0.52 15.83 ± 0.14 11.33 ± 0.22 10.86 ± 0.38
7f 83.22 ± 0.21 54.18 ± 0.35 43.66 ± 0.54 23.33 ± 0.26 13.75 ± 0.73 12.87 ± 0.23
7g 81.56 ± 0.48 52.28 ± 0.86 41.70 ± 0.74 14.62 ± 0.34 10.61 ± 0.28 10.34 ± 0.16
7h 82.62 ± 0.41 53.75 ± 0.75 42.44 ± 0.49 21.39 ± 0.29 12.60 ± 0.72 12.05 ± 0.37
7i 84.78 ± 0.64 55.71 ± 0.32 45.62 ± 0.94 28.55 ± 0.30 16.82 ± 0.37 14.98 ± 0.65
7j 87.89 ± 0.95 58.44 ± 0.88 48.17 ± 0.88 39.53 ± 0.23 23.29 ± 0.98 19.59 ± 0.41
7k 97.31 ± 0.74 88.16 ± 0.43 80.54 ± 0.54 70.48 ± 0.17 41.54 ± 0.91 42.25 ± 0.36
7l 95.13 ± 0.85 82.38 ± 0.27 75.26 ± 0.81 65.86 ± 0.47 38.81 ± 0.88 38.86 ± 0.28
7m 92.11 ± 0.88 71.15 ± 0.19 65 ± 0.46 56.88 ± 0.59 33.52 ± 0.57 31.85 ± 0.06
7n 90.57 ± 0.59 69.83 ± 0.31 61.97 ± 0.44 54.23 ± 0.32 31.96 ± 0.16 29.58 ± 0.75
7o 94.97 ± 0.73 76.63 ± 0.13 70.00 ± 0.93 61.26 ± 0.29 36.1 ± 0.64 35.05 ± 0.74
7p 89.82 ± 0.36 68.33 ± 0.79 61.77 ± 0.42 51.43 ± 0.36 30.31 ± 0.84 28.24 ± 0.62
7q 93.46 ± 0.54 72.41 ± 0.45 66.15 ± 0.69 57.89 ± 0.12 34.12 ± 0.37 32.71 ± 0.87
7r 96.33 ± 0.48 86.31 ± 0.21 78.85 ± 0.32 69.00 ± 0.05 40.66 ± 0.86 41.19 ± 0.94
7s 88.63 ± 0.67 59.87 ± 0.26 49.22 ± 0.24 43.07 ± 0.28 25.38 ± 0.46 21.38 ± 0.32
Doxorubicin 93.65 ± 0.42 87.54 ± 0.67 79.98 ± 0.67 69.98 ± 0.47 41.25 ± 0.79 42.08 ± 0.26
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The interactive structures were captured in energy minimized optimizations with 0.100 of minimum root 
mean standard deviation gradient and the binding modes are envisaged by UCSF  Chimera38. The binding energies 
of proper interactions of title compound ligands with target protein receptors in chain P of 4N5Y (hemagglutinin 
HA1 chain) for HT29, chain B of 1IGT (IGG2A intact antibody—MAB231) for MDAMB231 and chain A of 
2VWD (hemagglutinin-neuraminidase) for HEK293T cancer cell lines were considered and fond that 7a–s are 
effectively bound with the identified proteins as presented in Tables 4, 5, 6 and 7.
ADMET  properties39. ADMET properties of 7a–s have calculated on preADMET online  server40, which 
assisted to understand their ADMET potentialities In continuance, the prediction of tumarogenic, mutagenic, 
irritant and reproductive effects have assisted to ascertain the toxicity properties. All the ADMET properties 
were identified with in the potential limits of safe drugs as presented in Table 8.
QSAR studies. As ADMET properties are foremost requisites for drug candidates to reach clinical stage, 
in addition the oral bio-availability comprehends them by precise poise among partitioning and solubility as 
evolved from QSAR studies. Similarly, obeying Lipinski’s rule of  five41 is a notable tool for screening potentiality 
of newer molecules and was predicted by  Molinspiration42 software. The computation of Veber Rule and other 
parameters like partition coefficient (octanol to water) and percentage of absorption in addition fulfils the QSAR 
studies as presented the results in Table 9.
Bioactivity and toxicity risk studies. The QSAR descriptors of 7a–s have been predicted on molinspira-
tion online  server42 as properties were explored with molinspiration engine v2018.10 and bioactivity scores were 
explored with molinspiration engine v2018.03 and the results proved them as safer drugs. Similarly, the Osiris 
online property explorer  toolkit43 has provided the toxicity risks and drug properties as presented in Table 10. 
This study helped in understanding the physico-chemical interactions of the synthesized compounds against 
their targets and eventually facilitated in determining their drug properties.
BSA protein binding assay. The protein binding assay of title compounds was performed with Bovine 
serum albumin (BSA), a standard protein, to correlate their evaluated anticancer activity through mutual 
interactions, where such interactions made these anticancer agents as transportable in blood. The UV–Visible 
absorption spectroscopy has adapted to track the changes in the absorption bands induced by conformational 
change showing the formation of the protein bound compound. The binding constant  Kb predicted from the 
BSA protein binding assay was given in Table 11.
In assay, prepared standard BSA protein solution [2.5  mg in 10.0  mL of Tris–HCl buffer (5  mM 
Tris–HCl + 10 mM NaCl @ pH = 7.4) was preserved at refrigeration conditions. Title compound solutions were 
incubated at room temperature for nearly 30 min before the process. Then the UV–Visible absorption spectra 
of title compounds of a conserved concentration of 25 μM in combination with prepared BSA solutions ranging 
Table 3.  MTT assay of 7a–s against HEK293T.
Compound
Percentage of inhibition against treated concentrations (µM)
IC50 (µg/mL)1 5 10 25 50
7a 99.93 ± 0.11 98.52 ± 0.96 97.63 ± 0.45 96.81 ± 0.20 57.05 ± 0.81 65.53 ± 0.58
7b 98.93 ± 0.66 97.41 ± 0.57 96.44 ± 0.46 95.2 ± 0.29 55.11 ± 0.88 62.88 ± 0.45
7c 96.63 ± 0.53 94.28 ± 0.53 90.18 ± 0.38 83.28 ± 0.21 49.08 ± 0.23 52.51 ± 0.61
7d 99.76 ± 0.56 98.09 ± 0.42 97.1 ± 0.88 96.35 ± 0.19 56.78 ± 0.69 65.13 ± 0.44
7e 98.73 ± 0.97 97.08 ± 0.25 95.2 ± 0.76 91.72 ± 0.35 54.05 ± 0.77 60.22 ± 0.52
7f 92.96 ± 0.52 90.92 ± 0.52 88.07 ± 0.68 80.53 ± 0.41 47.46 ± 0.38 50.86 ± 0.39
7g 95.9 ± 0.54 92.62 ± 0.31 88.84 ± 0.07 81.24 ± 0.32 48.22 ± 0.86 51.22 ± 0.17
7h 92.81 ± 0.18 89.61 ± 0.31 86.2 ± 0.66 78.45 ± 0.18 46.23 ± 0.43 49.02 ± 0.12
7i 98.39 ± 0.19 95.73 ± 0.97 93.38 ± 0.64 88.56 ± 0.24 52.19 ± 0.26 57.14 ± 0.33
7j 96.71 ± 0.63 94.47 ± 0.83 91.28 ± 0.48 84.17 ± 0.37 49.6 ± 0.38 53.32 ± 0.47
7k 99.55 ± 0.46 97.77 ± 0.09 96.79 ± 0.17 95.46 ± 0.43 56.26 ± 0.12 64.18 ± 0.55
7l 96.44 ± 0.31 94.13 ± 0.23 89.65 ± 0.12 82.83 ± 0.54 48.82 ± 0.67 52.15 ± 0.60
7m 97.18 ± 0.28 94.73 ± 0.82 92.36 ± 0.46 86.88 ± 0.30 51.2 ± 0.07 55.84 ± 0.43
7n 96.84 ± 0.75 94.67 ± 0.59 92.02 ± 0.39 84.32 ± 0.28 49.69 ± 0.21 53.43 ± 0.36
7o 95.33 ± 0.63 91.17 ± 0.26 88.65 ± 0.11 80.68 ± 0.76 48.18 ± 0.79 51.18 ± 0.94
7p 96.23 ± 0.74 93.99 ± 0.91 89.17 ± 0.81 82.34 ± 0.34 48.53 ± 0.12 51.74 ± 0.87
7q 98.51 ± 0.12 96.21 ± 0.72 94.69 ± 0.34 91.34 ± 0.41 53.83 ± 0.58 60.01 ± 0.73
7r 97.98 ± 0.88 95.25 ± 0.68 92.81 ± 0.21 88.11 ± 0.25 51.93 ± 0.23 56.85 ± 0.67
7s 93.26 ± 0.88 91.78 ± 0.53 88.09 ± 0.54 80.57 ± 0.26 47.79 ± 0.79 51.06 ± 0.15
Doxorubicin 96.1 ± 0.83 95.66 ± 0.42 92.44 ± 0.56 85.27 ± 0.78 50.25 ± 0.14 54.38 ± 0.49
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from 5 to 500 μM were analyzed in the wavelength ranging from 200 to 400 nm. The UV–visible spectral stud-
ies were performed in a mixed solvent system (1:9 DMSO and Tris–HCl buffer) and absorption spectra were 
recorded by using 1-cm-path quartz cuvettes at room temperature. Then the Binding constant  Kb is calculated 
from Benesi–Hildebrand equation shown below. Where,  Ao and εf are the absorbance and molar extinction coef-
ficients of title compounds in free form, A and εb are absorbance and molar extinction coefficients of respective 




































7a 0 0 − 8.6095 2 2 2
Ligand(C=O)—GLY23(HN) 2.8935 Donor
Ligand(Pyr-N)—HSD25(HN) 2.9687 Donor
7b 0 3 − 8.4816 2 2 2
Ligand(C=O)—GLY23(HN) 2.8223 Donor
Ligand(Pyr-N)—HSD25(HN) 2.9202 Donor
7c 0 7 − 7.2184 2 2 2
Ligand(C=O)—GLY23(HN) 3.0877 Donor
Ligand(C=O)—HSD25(HN) 1.9558 Donor
7d 0 10 − 8.4880 2 2 2
Ligand(C=O)—GLY23(HN) 3.0911 Donor
Ligand(C=O)—PHE138(HN) 3.5888 Donor
7e 1 15 − 8.2767 2 2 2
Ligand(C=O)—GLY23(HN) 3.1952 Donor
Ligand(Pyr-N)—HSD25(HN) 2.8128 Donor
7f 0 0 − 8.8058 2 2 2
Ligand(C=O)—GLY23(HN) 2.8721 Donor
Ligand(Pyr-N)—HSD25(HN) 2.9898 Donor
7g 0 5 − 8.7595 2 2 2
Ligand(C=O)—GLY23(HN) 3.1550 Donor
Ligand(C=O)—HSD25(HN) 2.8423 Donor
7h 0 7 − 8.5984 2 2 2
Ligand(C=O)—GLY23(HN) 2.8549 Donor
Ligand(Thiop-S)—HSD25(HN) 3.6470 Donor
7i 0 3 − 8.8206 2 2 2
Ligand(C=O)—GLY23(HN) 2.9845 Donor
Ligand(C=O)—PHE138(HN) 3.4200 Donor
7j 0 1 − 8.3752 2 2 2
Ligand(C=O)—GLY23(HN) 2.9582 Donor
Ligand(Thiaz-N)—HSD25(HN) 2.8874 Donor
7k 0 3 − 8.3791 2 2 2
Ligand(C=O)—GLY23(HN) 3.4829 Donor
Ligand(C=O)—PHE138(HN) 3.3366 Donor
7l 3 0 − 7.8424 2 2 2
Ligand(C=O)—GLY23(HN) 2.1122 Donor
Ligand(C=O)—ALA7(HN) 2.8755 Donor
7m 2 3 − 8.4478 2 2 2
Ligand(C=O)—GLY23(HN) 1.9981 Donor
Ligand(C=O)—ALA7(HN) 2.7552 Donor
7n 1 2 − 8.4168 2 2 2
Ligand(C=O)—GLY23(HN) 2.1058 Donor
Ligand(C=O)—ALA7(HN) 2.8589 Donor
7o 0 18 − 9.0887 2 2 2
Ligand(C=O)—GLY23(HN) 3.0123 Donor
Ligand(C=O)—PHE138(HN) 3.1354 Donor
7p 0 20 − 8.1701 2 2 2
Ligand(C=O)—GLY23(HN) 2.9133 Donor
Ligand(C=O)—PHE138(HN) 3.4498 Donor
7q 1 3 − 8.4636 2 2 2
Ligand(C=O)—GLY23(HN) 3.9704 Donor
Ligand(C=O)—PHE138(HN) 3.3830 Donor
7r 1 2 − 8.4434 2 2 2
Ligand(C=O)—GLY23(HN) 3.9253 Donor
Ligand(C=O)—PHE138(HN) 3.3466 Donor
7s 0 0 − 8.3221 2 2 2
Ligand(C=O)—GLY23(HN) 2.5952 Donor
Ligand(Pyr-N)—PHE138(HN) 3.0020 Donor
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Results and discussion
Chemistry. The acridone fused piperazino-carboxamide derivatives (7a–s) synthesized in the present study 
are novel as the piperazine ring has been constructed on the bridged carbon (linking ring A and B) rather simply 
fusing on ring A or C of basic acridone skeleton. This kind of construction has evolved some triazolo-, imida-
zolo- and pyrimidino-fused acridones so far, this piperazine fused acridone frame linking alkyl/ aryl moieties 
with amide linker is a novel accomplishment to the existing array of acridones. As Pd(OAc)2–Xantphos is used 
as a potential catalyst–ligand system for C–N  coupling44, here we have extended the use of  Cs2CO3–Pd(OAc)2–
Xantphos system in producing the acridone ring by forming a C–N linkage through N-arylation process. The 
chemical structures of the synthesized compounds (7a–s) of the study were confirmed by IR, 1H, 13C and mass 
spectrometry analyses and all the spectral responses were observed in their expected standard range, and cor-

















7a 0 5 − 7.4821 2 2 2
Ligand(C=O)—TYR35(HO) 2.1563 Donor
Ligand(Pyr-N)—TYR58(HO) 4.0539 Donor
7b 7 0 − 7.2520 2 1 2
Ligand(C=O)—ILE260(HN) 4.1297 Donor
Ligand(C=O)—LYS261(HN) 4.3719 Donor
7c 13 4 − 7.4102 2 1 2
Ligand(C=O)—ILE260(HN) 4.3841 Donor
Ligand(C=O)—LYS261(HN) 4.6212 Donor
7d 13 0 7.3449 2 1 2
Ligand(C=O)—ILE260(HN) 3.6546 Donor
Ligand(C=O)—LYS261(HN) 4.1198 Donor
7e 12 0 − 7.4886 2 1 2
Ligand(C=O)—ILE260(HN) 4.1192 Donor
Ligand(C=O)—LYS261(HN) 4.3945 Donor
7f 7 6 − 7.4606 2 1 2
Ligand(C=O)—ILE260(HN) 4.1971 Donor
Ligand(C=O)—LYS261(HN) 4.5621 Donor
7g 4 1 − 7.3478 2 1 2
Ligand(C=O)—ILE260(HN) 4.1345 Donor
Ligand(C=O)—LYS261(HN) 4.4337 Donor
7h 24 0 − 7.2976 2 1 2
Ligand(C=O)—THR108(HO) 3.3480 Donor
Ligand(C=O)—GLU150(HN) 3.7851 Donor
7i 19 4 − 7.6623 2 1 2
Ligand(C=O)—ILE260(HN) 4.0903 Donor
Ligand(C=O)—LYS261(HN) 4.3806 Donor
7j 19 6 − 7.2855 2 1 2
Ligand(C=O)—ILE260(HN) 4.3141 Donor
Ligand(C=O)—LYS261(HN) 4.5155 Donor
7k 8 4 − 7.3750 2 1 2
Ligand(C=O)—ILE260(HN) 4.0838 Donor
Ligand(C=O)—LYS261(HN) 4.4159 Donor
7l 10 2 − 7.2863 2 1 2
Ligand(C=O)—ILE260(HN) 4.212 Donor
Ligand(C=O)—LYS261(HN) 4.3262 Donor
7m 10 1 − 7.4682 2 1 2
Ligand(C=O)—ILE260(HN) 4.2244 Donor
Ligand(C=O)—LYS261(HN) 4.4613 Donor
7n 12 0 − 7.5436 2 1 2
Ligand(C=O)—ILE260(HN) 4.1754 Donor
Ligand(C=O)—LYS261(HN) 4.4298 Donor
7o 7 2 − 7.6293 2 1 2
Ligand(C=O)—ILE260(HN) 4.1210 Donor
Ligand(C=O)—LYS261(HN) 4.4333 Donor
7p 8 1 − 7.3795 2 1 2
Ligand(C=O)—ILE260(HN) 4.1400 Donor
Ligand(C=O)—LYS261(HN) 4.4103 Donor
7q 10 0 − 7.3624 2 1 2
Ligand(C=O)—ILE260(HN) 4.1312 Donor
Ligand(C=O)—LYS261(HN) 4.4088 Donor
7r 7 1 − 7.4395 2 1 2
Ligand(C=O)—ILE260(HN) 4.1234 Donor
Ligand(C=O)—LYS261(HN) 4.3922 Donor
7s 13 2 − 7.1704 2 1 2
Ligand(C=O)—ILE260(HN) 4.3825 Donor
Ligand(C=O)—LYS261(HN) 4.5276 Donor
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responding mass spectral fragments were identified as their isotopic and daughter ion peaks at expected m/z 
with significant intensities.
Cytotoxic activity. Among the acridone derivatives (7a–s) screened for anticancer activity against human 
colorectal adenocarcinoma (HT29) cancer cell lines, 7l and 7k were identified to exert highest activity with 
68.88 and 66.23 of percentage of inhibition respectively and 7m–r exhibited moderate activity in the range 
of 59.26–54.13 percentage of inhibition. Similarly as screened against human breast adenocarcinoma (MDA-
MB-231) cancer cell lines, 7k, 7r, 7l and 7o have demonstrated significant activity with 70.48, 69.00, 65.86 
and 61.26 percentage of inhibition respectively and 7q, 7m, 7n and 7p have exhibited moderate activity in the 
range of 57.89–51.43 percentage of inhibition. Similarly as screened against human embryonic kidney (HEK-
293T) cancer cell lines almost all the compounds have exhibited the most significant activity in terms of per-
centage of inhibition in the range of 96.81–78.45, where 7a, 7d, 7k, 7b, 7e and 7q have exhibited 96.81, 96.35, 



















7a 10 4 − 7.6705 2 2 2
Ligand(C=O)—GLU226(HN) 3.2728 Donor
Ligand(Pyr-N)—LEU567(HN) 4.0462 Donor
7b 7 0 − 7.2520 2 1 2
Ligand(C=O)—LYS569(HN) 4.2550 Donor
Ligand(C=O)—ASN570(HN) 2.5205 Donor
7c 7 0 − 7.1106 2 1 2
Ligand(Pyr-N)—LEU448(HN) 2.9792 Donor
Ligand(Pyr-N)—GLY449(HN) 3.7353 Donor
7d 0 0 − 7.2749 2 2 2
Ligand(C=O)—GLY227(HN) 2.4572 Donor
Ligand(C=O)—LYS569(HN) 4.1546 Donor
7e 13 5 − 7.5182 2 2 2
Ligand(Pyr-N)—GLY227(HN) 2.3756 Donor
Ligand(C=O)—LYS569(HN) 2.3751 Donor
7f 13 1 − 7.3895 2 2 2
Ligand(Pyr-N)—GLY227(HN) 4.1946 Donor
Ligand(C=O)—LEU448(HN) 4.0997 Donor
7g 2 3 − 7.3397 2 2 2
Ligand(C=O)—GLY227(HN) 3.1459 Donor
Ligand(C=O)—LEU448(HN) 3.1550 Donor
7h 0 4 − 7.4982 2 2 2
Ligand(Thiop-S)—ASP257(HN) 3.7906 Donor
Ligand(C=O)—LYS569(HN) 2.8464 Donor
7i 3 7 − 8.1394 2 2 2
Ligand(Pyr-N)—MET224(HN) 4.3168 Donor
Ligand(C=O)—LEU567(HN) 3.0713 Donor
7j 0 0 − 7.5193 2 1 2
Ligand(Thiaz-S)—ARG435(HN) 3.6283 Donor
Ligand(Thiaz-S)—LYS465(HN) 4.3091 Donor
7k 17 0 − 7.3786 2 2 2
Ligand(HO)—GLY214(HN) 2.3554 Donor
Ligand(C=O)—LYS591(HN) 1.8494 Donor
7l 6 2 − 7.3860 2 2 2
Ligand(C=O)—GLY227(HN) 2.3839 Donor
Ligand(C=O)—LYS569(HN) 4.1170 Donor
7m 9 6 − 7.2792 2 1 2
Ligand(C=O)—CYS395(S) 5.2391 Donor
Ligand(C=O)—LEU436(HN) 2.8589 Donor




7p 1 1 − 7.1904 2 1 2
Ligand(C=O)—ARG435(HN) 2.0468 Donor
Ligand(C=O)—ARG435(HN) 3.2292 Donor
7q 24 1 − 7.3226 2 1 2
Ligand(C=O)—ARG548(HN) 1.8235 Donor
Ligand(C=O)—ARG548(HN) 3.1213 Donor
7r 4 4 − 7.5366 2 2 2
Ligand(C=O)—GLY227(HN) 2.4060 Donor
Ligand(C=O)—LYS569(HN) 4.1669 Donor
7s 4 0 − 6.9915 2 1 2
Ligand(Pyr-N)—LYS569(HN) 2.1221 Donor
Ligand(Pyr-N)—ASN570(HN) 4.4184 Donor
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Binding with 4N5Y of HT29 Binding with 1IGT of MDAMB231 Binding with 2VWD of HEK293T
Compound 7a Compound 7a Compound 7a
Compound 7b Compound 7b Compound 7b
Compound 7c Compound 7c Compound 7c
Compound 7d Compound 7d Compound 7d
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Binding with 4N5Y of HT29 Binding with 1IGT of MDAMB231 Binding with 2VWD of HEK293T
Compound 7f Compound 7f Compound 7f
Compound 7g Compound 7g Compound 7g
Compound 7h Compound 7h Compound 7h
Compound 7i Compound 7i Compound 7i
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Binding with 4N5Y of HT29 Binding with 1IGT of MDAMB231 Binding with 2VWD of HEK293T
Compound 7k Compound 7k Compound 7k
Compound 7l Compound 7l Compound 7l
Compound 7m Compound 7m Compound 7m
Compound 7n Compound 7n Compound 7n
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Binding with 4N5Y of HT29 Binding with 1IGT of MDAMB231 Binding with 2VWD of HEK293T
Compound 7p Compound 7p Compound 7p
Compound 7q Compound 7q Compound 7q
Compound 7r Compound 7r Compound 7r
Compound 7s Compound 7s Compound 7s
Doxorubicin Doxorubicin Doxorubicin
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Table 8.  ADMET properties predicted for compounds 7a–s. a BBB (Blood–Brain Barrier) 
penetration = [Brain]/ [Blood]; bCaco-2 cells derived from human colon adenocarcinoma, possessing multiple 
drug transport pathways through intestinal epithelium; cHIA (Human intestinal absorption), the sum of 
absorption and bioavailability evaluated from ratio of excretion in urine, bile and feces etc.; dMDCK cell 
system is used as tool for rapid permeability screening; e% of drug that binds to plasma protein; fin vitro Ames 
test by Metabolic and Non-metabolic activated TA100 and TA1535 strains collected from rat liver homogenate.
Entry
In vivo blood–brain barrier 
penetration (C. brain/C. 
blood)a




In vitro MDCK cell 
permeability (nm/s)d
In vitro plasma
protein binding (%)e Toxicityf
7a 2.5177 40.1997 97.3627 215.3520 98.4091 Negative
7b 1.7088 33.8868 97.3627 33.1032 94.5608 Negative
7c 0.6783 35.9472 97.3627 38.6052 95.3119 Negative
7d 0.6990 42.4307 97.8198 81.3338 89.9324 Negative
7e 2.4518 44.8823 97.3643 74.8252 97.2246 Negative
7f 2.9893 42.2071 97.3643 37.7509 96.8717 Negative
7g 2.4944 42.3708 97.3643 144.9730 96.9384 Negative
7h 2.6465 31.2874 97.6281 33.3530 89.4191 Negative
7i 0.1523 25.8135 97.3668 0.0526 97.6000 Negative
7j 0.9136 44.8966 98.7226 183.6750 92.4212 Negative
7k 0.3451 21.6738 96.2654 1.5542 92.0128 Negative
7l 3.7909 42.2821 97.9994 33.6899 95.9548 Negative
7m 0.3443 28.7804 98.0547 0.0890 91.5915 Negative
7n 0.1846 28.1250 98.0547 0.0454 94.6528 Negative
7o 0.2196 28.4536 98.0547 0.0483 89.0836 Negative
7p 2.8566 39.6531 98.0029 8.8231 91.9695 Negative
7q 2.4562 40.4987 98.0029 2.1707 90.7872 Negative
7r 1.8993 34.4524 97.3623 64.6242 94.1251 Negative
7s 1.7088 33.8868 97.3627 33.1032 94.5608 Negative
Doxorubicin 0.0328 17.7265 31.9529 1.0236 32.7895 Negative
Table 9.  QSAR properties of 7a–s. MW: Molecular weight; HB Don: Hydrogen bond donors (n ON); HB 
Acc: Hydrogen bond acceptors (n OH NH); logP: log of octanol to water partition coefficient; MR: Molecular 
refractivity  (cm3/mol); Lip. Vio.: Lipinski Violations; TPSA: Total polar surface area (A°)2; No. of RB: Number 
of rotatable bonds; Veb. Vio.: Veber Violations; No. of ‘H’: Number of Hydrophobic Atoms; V.Vol.: Van der 
Waals volume; ρ: Density (gm/cc); S: Solubility; CLP: ClogP; % ABS: % of absorption;
Entry
Lipinski parameters Veber parameters Other parameters
MW HB Don HB Acc logP (o/w) MR Lip. Vio TPSA No. of RB Veb. Vio No. of H V.Vol ρ S CLP % ABS
7a 341.37 5 0 1.63 96.38 0 55.21 1 0 15 298.16 1.44 − 5.55 3.48 89.95
7b 341.37 5 0 1.56 96.38 0 55.21 1 0 15 298.16 1.44 − 5.52 3.43 89.95
7c 341.37 5 0 1.51 96.38 0 55.21 1 0 15 298.16 1.44 − 5.52 3.43 89.95
7d 318.38 4 0 1.56 90.33 0 42.31 2 0 18 287.3 1.37 − 5.94 3.76 94.40
7e 355.40 5 0 1.68 101.01 0 55.21 1 0 17 314.72 1.41 − 5.92 3.88 89.95
7f 355.40 5 0 2.08 101.01 0 55.21 1 0 17 314.72 1.41 − 5.89 3.83 89.95
7g 355.40 5 0 2.41 101.01 0 55.21 1 0 17 314.72 1.41 − 5.89 3.83 89.95
7h 346.41 4 0 2.39 96.72 0 42.31 1 0 14 293.03 1.48 − 6.22 4.21 94.40
7i 409.37 5 0 2.59 101.37 0 55.21 2 0 14 329.46 1.53 − 6.35 4.38 89.95
7j 319.39 4 0 2.52 94.52 0 38.13 1 0 13 269.89 1.53 − 6.62 4.37 95.85
7k 356.38 5 1 2.32 100.11 0 62.54 1 0 16 310.33 1.48 − 6.02 4.08 87.42
7l 340.38 4 0 2.80 98.58 0 42.31 1 0 16 302.32 1.40 − 6.32 4.43 94.40
7m 408.38 4 0 3.65 103.57 0 42.31 2 0 15 333.61 1.49 − 7.1 5.28 94.40
7n 408.38 4 0 3.67 103.57 0 42.31 2 0 15 333.61 1.49 − 7.1 5.28 94.40
7o 408.38 4 0 3.69 103.57 0 42.31 2 0 15 333.61 1.49 − 7.1 5.28 94.40
7p 358.37 4 0 2.91 98.70 0 42.31 1 0 15 307.25 1.44 − 6.63 4.53 94.40
7q 358.37 4 0 2.94 98.70 0 42.31 1 0 15 307.25 1.44 − 6.63 4.53 94.40
7r 358.37 4 0 2.96 96.49 0 42.31 1 0 14 307.25 1.49 − 6.63 4.53 94.40
7s 313.36 4 0 2.39 96.38 0 38.13 1 0 15 279.18 1.44 − 6.09 3.47 95.85
Doxorubicin 543.52 12 7 0.57 131.52 3 206.08 5 0 29 459.18 1.61 − 4.51 0.17 37.90
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Table 10.  Bioactivity scores, drug properties and toxicity risks of 7a–s. GPCRL: G protein-coupled receptor 
ligand; ICM: Ion channel modulator; KI: Kinase inhibitor; NRL: Nuclear receptor ligand; PI: Protease 
inhibitor; EI: Enzyme inhibitor; Mut: Mutagenic; Tum: Tumorigenic; Irrit: Irritant; R.E.: Reproductive effect.
Entry
Bioactivity Drug properties Toxicity risks
GPCRL ICM KI NRL PI EI Drug-likeness Drug score Mut Tum Irrit R.E
7a 0.24 − 0.09 0.04 − 0.28 − 0.01 0.23 4.82 0.58 Nil Nil Nil Nil
7b 0.22 − 0.10 0.12 − 0.26 − 0.11 0.19 5.94 0.59 Nil Nil Nil Nil
7c 0.19 − 0.12 0.12 − 0.25 − 0.11 0.17 5.11 0.58 Nil Nil Nil Nil
7d 0.32 − 0.14 0.01 − 0.16 0.04 0.18 5.32 0.54 Nil Nil Nil Nil
7e 0.21 − 0.15 − 0.04 − 0.30 − 0.05 0.16 4.64 0.52 Nil Nil Nil Nil
7f 0.19 − 0.16 − 0.02 − 0.29 − 0.08 0.16 4.64 0.52 Nil Nil Nil Nil
7g 0.23 − 0.09 − 0.04 − 0.27 − 0.02 0.18 4.71 0.52 Nil Nil Nil Nil
7h 0.16 − 0.22 − 0.02 − 0.34 − 0.18 0.06 5.72 0.29 Risk Nil Nil Nil
7i 0.23 − 0.02 − 0.02 − 0.14 0.00 0.21 − 2.49 0.23 Nil Nil Nil Nil
7j − 0.01 − 0.36 0.02 − 0.46 − 0.36 0.24 4.37 0.45 Nil Nil Nil Nil
7k 0.18 − 0.14 0.04 − 0.09 − 0.13 0.15 5.05 0.50 Nil Nil Nil Nil
7l 0.15 − 0.18 0.01 − 0.22 − 0.14 0.11 4.73 0.46 Nil Nil Nil Nil
7m 0.18 − 0.09 0.06 − 0.04 − 0.11 0.11 − 6.11 0.17 Nil Nil Nil Nil
7n 0.19 − 0.09 0.05 − 0.07 − 0.10 0.10 − 5.58 0.17 Nil Nil Nil Nil
7o 0.18 − 0.09 0.05 − 0.08 − 0.10 0.10 − 5.99 0.17 Nil Nil Nil Nil
7p 0.13 − 0.22 0.03 − 0.19 − 0.16 0.10 3.50 0.43 Nil Nil Nil Nil
7q 0.16 − 0.18 0.04 − 0.19 − 0.14 0.09 0.86 0.37 Nil Nil Nil Nil
7r 0.15 − 0.19 0.03 − 0.20 − 0.16 0.09 4.23 0.43 Nil Nil Nil Nil
7s 0.27 0.06 0.17 − 0.10 − 0.06 0.25 3.93 0.52 Nil Nil Nil Nil
Doxorubicin 0.20 − 0.20 − 0.07 0.32 0.67 0.66 7.19 0.33 Nil Nil Risk Nil
Table 11.  The BSA protein binding constants  (Kb) of 7a–s.
Entry λmax (nm) Kb  (M−1) Entry λmax (nm) Kb  (M−1)
7a 280 1.3042 × 104 7k 280 0.9450 × 104
7b 280 1.2800 × 104 7l 280 1.0085 × 104
7c 280 1.1943 × 104 7m 280 1.1029 × 104
7d 280 1.2944 × 104 7n 280 1.1813 × 104
7e 280 1.4140 × 104 7o 280 1.0175 × 104
7f 280 1.4033 × 104 7p 280 1.1926 × 104
7g 280 1.5156 × 104 7q 280 1.0876 × 104
7h 280 1.3785 × 104 7r 280 1.0792 × 104
7i 280 1.5415 × 104 7s 280 1.1661 × 104
7j 280 1.2693 × 104 Doxorubicin 280 0.7865 × 104
Figure 2.  Hydrophobic surface protein–ligand interface in 7i.
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95.46, 95.20, 91.72 and 91.34 of percentage of inhibition respectively and remaining compounds have exhibited 
the moderate activity in the range of 88.56–78.45 of percentage of inhibition. The potential compounds 7k, 
7r, 7l, 7o, 7a, 7d, 7b, 7e, 7i and 7q having the substitutions like p-hydroxybenzoyl, p-fluorobenzoyl, benzoyl, 
p-(trifluoromethyl)benzoyl, picolinoyl, cyclopropyl-acetyl, 3-nicotinoyl, 6-methylpicolinoyl, trifluoromethylpi-
colinyl and 3-fluorobenzoyl groups on acridone fused piperazine moiety. The significant inhibition of title com-
pounds is due to the greater electron releasing capacity, better intermolecular hydrogen bonding interactions, 
higher electronegativity, molecular volume and steric hindrance, which are making them to get interact with 
targeted cell lines and have boosted the pharmacokinetic, physicochemical, liphophilic, properties of the title 
compounds that led to the metabolic destruction of  cells45. Significantly the tested profiles on HEK293T normal 
cell lines revealed them as safer compounds which are more potent against HT29 and MDA-MB-231 cell lines 
as shown in Tables 1, 2 and 3.
Molecular docking studies. The in vitro cell proliferation inhibition of 7a–s against HT29, MDAMB231 and 
HEK293T has been supported by correlating the binding potentialities of 7a–s with their corresponding enzymatic 
protein chains. In concern the molecular docking was performed for the structures of 7a–s against chain P of 4N5Y 
(hemagglutinin HA1 chain) for HT29, chain B of 1IGT (IGG2A intact antibody—MAB231) for MDA-MB-231 and 
chain A of 2VWD (hemagglutinin-neuraminidase) for HEK293T cell  lines46 to study the ligand–protein binding 
interactions. The binding interactions of aminoacid residues with hydrogen bond donors and acceptors of the 7a–s 
and their docking postures were presented in Tables 4, 5, 6 and 7. The binding specificity of 7a–s with the selected 
protein chains (4N5Y, 1IGT and 2VWD) that proliferates the cancerous cells growth will be arrested and acts as 
anticancer agents. As 7a–s binds with chain P of 4N5Y for HT29, chain B of 1IGT for MDAMB231 and chain A of 
2VWD for HEK293T cancer cell lines. Remarkably they have selectively bound to glycine (GLY), histidine (HSD), 
phenyl alanine (PHE), alanine (ALA) of 4N5Y with a binding energy ranging from − 9.0887 to − 7.2184 kcal/mol. 
Similarly bound to tyrosine (TYR), isoleucine (ILE), lysine (LYS), threonine (THR) and glutamic acid (GLU) of 
1IGT with a binding energy ranging from − 7.6623 to − 7.1704 kcal/mol. Likewise bound to leucine (LEU), aspara-
gine (ASN), methionine (MET), arginine (ARG), cysteine (CYS), glycine (GLY), lysine (LYS) and glutamic acid 
(GLU) of 2VWD with a binding energy ranging from − 8.1394 to − 6.9915 kcal/mol. The intense analysis discloses 
that neutral aminoacids are strongly bound to the ligands than basic than acidic aminoacids. The hydrophobic 
surface protein–ligand interfacial interactions in 7i have been shown in Fig. 2.
ADMET properties. The investigation of ADMET properties for a group of analytes under study assists to 
comprehend the physico-chemical interactions of those analytes and helps us to evaluate their drug-likeness 
properties. This type of high-throughput screening helps in distinguishing a lead compound of a large group 
in the fascinated domain of a  target47. This critical study assists in identifying the pharmacokinetic proper-
ties of 7a–s and to unveil their drug-like interactions. The Human intestinal absorption describes carrying of 
the effective composites to the target cell tissues via blood stream and made them to interact mutually. In oral 
administration of a drug-like compound its degree of absorption has been considered, where it again depends 
on its inherent bioavailability properties. There the absorbed quantity of compound be itself distributed into 
the muscles and there to other organs by the circulation via extracellular sites. Then the compound’s distribu-
tion lowers its plasma concentration independently and then metabolizes, from there those metabolites will be 
distributed by the enzymatic redox reactions. In pharmacological aspects, potential metabolites distributed will 
work proficiently on cellular systems, inactive metabolites deactivates the administered compound and dimin-
ishes its effect in vivo, and the inert metabolites will be automatically excreted from kidneys.
The analysis of the obtained ADMET properties (Table 8) of 7a–s informed that the in vivo BBB penetra-
tion potentiality ratio is effective with a range of 0.1523–3.7909 and confirms their high CNS significance and 
approves their greater permeability permeability for the self-distribution in vivo. It is strengthened on the basis 
of their in vitro Caco-2 cell permeability perceived with 21.6738–44.8966 nm/s range, which institutes their 
persistent permeability to bind with plasma proteins and to penetrate in to BBB system. The in vitro PPB affinity 
in 89.0836–98.4091% range authorizes the robust binding capability of the compounds to plasma proteins. The 
in vitro MDCK cell permeability in 0.0454–215.3520 nm/s range reveals them as good permeable. Similarly the 
%HIA in the range of 96.2654–98.7226 ratio assures their interactions with the proper species in the anticipating 
target of domains. The negative sign of the toxicity predictions indicate that compounds 7a–s are non-toxic and 
safer drugs. Inclusively this ADMET analysis has been revealed the potential physico-chemical interactions of 
7a–s and their drug-likeness properties.
QSAR studies. QSAR results (Table  9) indicate that analogues 7a–s under study with molecular weights 
ranging from 409.37 to 313.36 (less than 500 daltons) demonstrated log P in the range of 3.69 to 1.51 (less than 5) 
suggesting their better permeability through cell membranes. Similarly number of hydrogen bond acceptor and 
donors are in the line of Lipinski’s rule as < 10 and < 5 respectively. The molecular refractivity from 90.33 to 103.57 
 cm3/mol as in the standard range i.e., 40–130  cm3/mol ascertains as all analogues are obeying the Lipinski rule of 
five and all they are considerably orally active drugs with good drug likeness properties. Moreover the total polar 
surface area contributed by the sum of polar atoms such as oxygen, nitrogen and attached  hydrogens48, which is 
ranging from 38.13 to 62.54 is also obeying the Veber rule as it is less than 140 Å2. Hence, these molecules are 
estimated to be easily diffused, absorbed and transported. Here the total polar surface area is very much correlated 
with the hydrogen bonding of a molecule and is associated with the transport properties of drug across the mem-
branes, prediction in the BBB and intestinal crossing. Molecules with total polar surface area in the range ≤ 160 
Å2 have good intestinal absorption and ≤ 60 Å2 has BBB  penetration49. Total polar surface area for the examined 
successions all the offshoots have come out to be best intestinal absorbers. On the other hand the number of rotat-
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able bonds in all the compounds are limited to 1–2 which is as per the Veber rule (i.e., less than 7) and hence in 
total they also obeying the Veber’s rule and again ascertains them as orally administrable drugs. Furthermore, the 
percentage of absorption ranging from 87.42 to 95.85, density in the range of 1.37 to 1.53 gm/cc, solubility ranging 
from − 5.52 to − 7.10, Van der Waals volume in the range 269.89 to 333.61 Å3 and ClogP in the range of 3.43 to 5.28 
ascertains all the compounds as significantly safer drug-like compounds. These calculations are in understanding 
the physico-chemical interactions of synthesized analogues with their targets and eventually helped in determin-
ing their drug properties by associating with the bioactivity and toxicity risks studies.
Bioactivity and toxicity risk studies. The prediction of bioactivity and toxicity risk studies of the syn-
thesized analogues 7a–s (Table 10) revealed their bioactivity properties like GPCR ligand property, ion chan-
nel modulator, kinase inhibitor, nuclear receptor ligand interactions, protease inhibitor and enzyme inhibitor 
interactions, and drug properties like drug-likeness and drug scores have measured and ascertained as potential 
non-toxic molecules. This Molinspiration prediction extensively helps to investigate the cheminformatics of 
the compounds under study by correlating with the database of in vitro and in vivo studies of established drugs 
based on mutual functional group similarity.
The toxicity risk results clearly indicate that 7a–s are safer as showing low or no risks of mutagenicity, tumo-
rigenicity, irritant and low or no effect on reproductive system and conformed drug like behavior. The positive 
value of drug likeness states that the molecule contains predominantly fragments which are frequently present 
in commercial drugs whereas majority of compounds accounts for negative  values38. Solubility is an important 
factor which aids in the movement of a compound from the site of administration into the blood stream and 
poor solubility leads to poor  absorption50. Alike drug score is a harmonizing parameter of druglikeness, ClogP, 
logS, molecular weight and toxicity risks and used to judge the compound’s overall potential to qualify for a drug. 
Ultimately it is predicted that all the synthesized analogues 7a–s exhibited higher scores than the standard drug.
Structure activity relationship studies. The comparative structural analysis infers that amide linker is 
beneficial as it highly elevated the activity of all the compounds. In over-all increase in number of hetero atoms 
in 7h (thiophene) and 7j (thiazole) increased the activity among the tested array of cells. Similarly among the 
positional isomers 7a (2-pyridyl), 7b (3-pyridyl) and 7c (4-pyridyl), nitrogen atom at second position in 7a is 
diminishing the activity and its lower commotion is due to lone pair-lone pair repulsions present on the oxygen 
and nitrogen (Fig. 3). Ultimately, nitrogen at fourth and third positions is more favourable for stimulating the 
activity. Similarly, isomer series of 7m (o-CF3), 7n (m-CF3) and 7o (p-CF3) and 7p (o-F), 7q (m-F) and 7r (p-F), 
have followed the activity trending in the order of meta > para > ortho by following the negative inductive effect 
and demonstrated the higher activity for meta position over other two. In the series of 7e–g, the increasing order 
of activity is observed as 7g (3-methylpicolinoyl) < 7e (6-methylpicolinoyl) < 7f (5-methylpicolinoyl) as di func-
tional substitutions diminishing the activity based on steric factors. In brief, the para substituted compounds 
with respect to the amide bond are acting as electron releasing groups and improving the activity (Fig. 3).
Figure 3.  SAR and structural effect of amide bond on 7a–s. 
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BSA protein binding assay. The study of BSA protein binding interactions of a drug substance infers 
about its possible transportability with BSA, as it is a standard protein carrier for almost all drugs and metabo-
lites. Here, all the title compounds were identified as potentially bound to the BSA protein, compounds 7i, 7g, 
7e and 7f having 2-trifluoromethyl, 2-methyl, 5-methyl and 4-methyl substitutions on picolinoyl groups were 
exhibited the highest binding constant  (Kb) values (Table 11) and absorption maxima at 280 nm and showed 
the hyperchromic effect. The values for these ranging from 1.5415 × 104 M−1 to 1.4033 × 104 M−1 are better in 
comparison to the Doxorubicin drug standard (0.7865 × 104 M−1) of the study. Hence, the BSA protein binding 
assay also ascertained the drug properties of the title compounds along the cytotoxic activity screened for them.
Conclusion
An array of novel tetracyclic acridone derivatives (7a–s) have been synthesized in good yields from quinoxaline, 
where  Cs2CO3–Pd(OAc)2–Xantphos used as a potential catalytic system in generating the acridone ring by form-
ing a C–N linkage. Similarly, the anticancer activity evaluation had revealed that 7k, 7r, 7l, 7o, 7a, 7d, 7b, 7e, 
7i and 7q were identified as effective anticancer agents as assessed by MTT assay against HT29, MDAMB231 
and HEK293T cancer cell lines. In addition, the molecular docking studies, QSAR, ADMET, bioactivity and 
toxicity risk properties predicted for them have strengthened their drug-likeness and were well correlated with 
in vitro anticancer activity and BSA protein binding assay results. The BSA binding studies confirms the stronger 
bond of title compounds with BSA as evidenced from the binding constants ranging from 1.5415 × 104 M−1 to 
1.4033 × 104 M−1 than the Doxoruicin drug reference. The molecular docking studies have inferred that com-
pounds 7a–s have potentially bound to Glycine and Lysine (neutral aminoacids) present on enzymatic proteins 
4N5Y, 1IGT and 2VWD with a binding energy ranging from − 9.0887 to − 6.9915 kcal/mol. These potential 
inter molecular hydrogen bonding interactions between hydrogen atoms of amides of enzymatic proteins and 
carbonyl groups of acridinone and 1-piperazinoyl fragments are responsible for cell growth inhibition by 7a–s. 
Ultimately, compounds 7a–s were identified as potential excitatory protein donor antagonists to reduce and 
block the cell functionality by neuronal damages and death of the cells. Therefore the idea of fusing acridone 
core with piperazine ring and linking various alkyl/ aryl/ heteroaryl to them via piperzinoyl carbon has been 
ascertained as an admiring task in designing these potential anticancer agents. Prospectively this study is serving 
as a trustworthy tool in accomplishing more potential acridone derivatives by novel structural modifications in 
7a–s, which are under study and are exercising for higher activity. These results demonstrate strong evidence 
for innovative investigations involving in designing more analogous compounds and methodologies to explore 
mechanistic aspects of their anticancer activity.
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